Stay updated with breaking news from Liminal Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced today...
Updated Business Strategy Focused on Small Molecule Therapeutics Kedrion to acquire, for a total of USD 17M, 2 plasma collection centers and an option to...
Liminal BioSciences Announces First Subject Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of Fezagepras News provided by Share this article Share this article LAVAL, QC, and CAMBRIDGE, England, Dec. 15, 2020 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, today announced that the first subject has been dosed in the Company's fezagepras Phase 1 multiple ascending dose clinical trial in healthy volunteers. The new clinical trial is designed to look at more frequent daily dosing (twice and thr...